~~<i id='41542DDEDF'><strike id='41542DDEDF'><tt id='41542DDEDF'><pre id='41542DDEDF'></pre></tt></strike></i>~~

Home» Wikipedia» explore

explore

author：entertainment 2025-09-06 10:14:46 Page View：34

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to address the problem of discarded donor organs
Next article： Novavax promises a turnaround & Lilly roils the obesity market

Wikipedia

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Pig kidney works a record two months in donated body

RelativesofMaurice“Mo”Miller—MaryMiller-Duffy,hissister(right),andherwife,SueDuffy—standwithhisbodya

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Acelyrin, a rare IPO success, stumbles in its first big test

MarkLennihan/APThebiotechcompanyAcelyrin,whichraisedmorethan$500millioninanIPOthisyear,ranintoitsfir